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Abstract: The bisphosphonate (BP) family of drugs has been used as a vital component in cancer therapy and many other 
diseases. One of the main adverse effects related to (BP) is BP-associated osteonecrosis of the jaw (ONJ). Although this 
condition was first recognized in 2003, the pathophysiologic mechanism remains undefined. Our hypothesis is that ONJs 
clinical course and delayed wound healing is in part correlated to a localized non-traditional calciphylaxis. This effect is 
identified by the evidence of calcium deposition in the connective tissue and around small blood vessels in the soft tissues 
immediately adjacent to ONJ lesions. This phenomenon helps to fill gaps in the cascade of events which leads to soft  
tissue ischemia, necrosis, and non-healing ONJ lesions. Our finding adds to the current knowledge of the potential   
pathophysiologic mechanisms related to ONJ.  
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INTRODUCTION 
Every year, an estimated 24 million bisphosphonate (BP) 
prescriptions are written in the U.S. alone
  [1].
  One of the 
more recently reported serious adverse effects of BP treat-
ment is BP-associated osteonecrosis of the jaw (ONJ). This 
condition was first recognized in 2003 and is predicted to 
occur in up to 28% of IV BP patients, with an estimated 
weighted prevalence of 13.3% in studies with accurate fol-
low-up [2]. 
Currently, ONJ lacks a defined pathophysiologic mecha-
nism. Unfortunately, researchers initially ignored the cross 
talk between bone and oral mucosal soft tissue, as this condi-
tion is truly a chemonecrosis process. Recently, we investi-
gated an oral soft tissue mechanism as a potential contributor 
to the initiation of ONJ and more importantly, an inhibitor of 
wound healing, secondary to free BP [3-5]. Now we add to 
this hypothesis, a potentially distinct and complementary 
mechanism of initiation and persistence of ONJ, secondary 
to a local non-traditional calciphylaxis through vascular and 
soft tissue calcium deposition [6] (Fig. 1).  
MATERIAL AND METHODS 
We  reviewed the tissue archives of the University of 
Maryland, Baltimore, Oral Pathology Consultants from 2003 
to 2011 (with IRB approval) and found 10 cases of diag-
nosed ONJ which contained adjacent soft tissue. Paraffin 
embedded tissue sections from these 10 stage 3 (AAOMS) 
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ONJs in cancer patients using zoledronic acid (bone and ad-
jacent soft tissue), were first evaluated using hematoxylin 
and eosin stain for accurate diagnosis. Next, unstained sec-
tions were deparaffinized, immersed in ethanol 100% and 
95%, washed with distilled H2O and incubated with 1% sil-
ver nitrate solution under UV light for 2 hours. The sections 
were then washed with distilled H2O and 5% sodium thio-
sulfate for 5 minutes. Next the sections were counterstained 
with nuclear fast red for 5 minutes. As a negative control, 
sections were treated with phosphate-buffered saline with 
omission of the von Kossa stain. Additionally, five normal 
archived oral mucosal tissues were used as a control. The 
von Kossa staining was reviewed by two independent, certi-
fied Oral Pathologists (MS and NB).  
RESULTS 
Using von Kossa staining, we demonstrated the presence 
of calcium in 8 of the 10 ONJ cases within the connective 
tissue and surrounding blood vessels. (Fig. 1A, B) All of 
these cases demonstrated a significant delay in ONJ wound 
healing. The bone within these specimens also demonstrated 
the presence of calcium at their leading edge where BP 
would typically bind to calcium phosphate since they are 
considered analogs of pyrophosphate [7] (Fig. 1C).  Five 
normal archived oral mucosal tissues were used as a control. 
(Fig. 1D). 
DISCUSSION 
Calciphylaxis is classically defined as a multifactorial re-
nal phenomenon, whereby microcalcification of small blood 
vessels leads to soft tissue ischemia, necrosis and non-
healing lesions [6]. This classic presentation is frequently 6    The Open Dentistry Journal, 2012, Volume 6  Meiller et al. 
fatal and is seen most often at end-stage renal failure [8]. 
However, in certain hypercalcemic states, such as malig-
nancy (Breast and Multiple Myeloma), hyperparathyroidism, 
cirrhosis, Crohns and collagen disease conditions, a non-
uremic non-traditional calciphylaxis is shown to induce vas-
cular and tissue deposition of calcium in the submucosal 
tissues [6-12]. This complication must surpass a critical 
threshold of sensitizing conditions (e.g. hypercalcemia and 
inflammation of malignancy; and BP and corticosteroid use) 
and thrombogenic stimuli (e.g. dental trauma). Since the 
mandible is a primary site for BP saturation and is com-
monly affected by trauma, infection and inflammation; an 
acidic microenvironment would release free BP from bone 
and secondarily release calcium from its BP bound state to 
induce oral mucosal apoptosis/necrosis [4, 7, 13, 14]. 
Clinically, ONJ is observed as a mucosal dehiscence 
leading to the formation of a superficial mucosal ulcer, 
which continues to extend with time and results in detectable 
bone exposure, necrosis and sequestration. Moreover, like 
calciphylaxis, these lesions typically present as non-healing 
wounds treated empirically. Once a lesion occurs, there is 
tremendous difficulty in treating these lesions, which leads 
to delayed or refusal of dental treatment and discontinuation 
of necessary cancer therapy. Currently, the only therapeutic 
regimen is antimicrobial therapy, with surgical interventions 
reserved only for severe cases. Therefore, a tetralogical cas-
cade must exist, including a combination of effects on bone, 
vasculature, microbial biofilm and oral mucosal soft tissues, 
especially in wound healing.  
CONCLUSION 
Part of the treatment regimen for calciphylaxis includes 
antibiotics and rebalancing calcium and phosphate, while 
avoiding local tissue trauma, similar to ONJ. Interestingly, 
the standard therapeutic regimen for ONJ, amoxicillin, is not 
affected by calcium and appears to have better success than 
tetracyclines which lose activity in the context of high cal-
cium levels. Perhaps balancing the calcium and phosphate 
levels, and creating a neutral pH, along with the standard of 
care therapy of eliminating the bacterial load, may become a 
translational model for investigating potential pathogenesis 
directed therapeutics. 
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